This Article Figures Only Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (56) Citing Articles via Google Scholar Google Scholar Articles by Lichtenberg, F. R. Search for Related Content PubMed PubMed Citation Articles by Lichtenberg, F. R. Related Collections Pharmaceuticals Health Spending

DataWatch

Are The Benefits Of Newer Drugs Worth Their Cost? Evidence From The 1996 MEPS

This study analyzes data on prescribed medicines from the 1996 Medical Expenditure Panel Survey (MEPS) to examine the association between the use of newer medicines and morbidity, mortality, and health spending. We find that people consuming newer drugs were significantly less likely to die by the end of the survey and were significantly less likely to experience work-loss days than were people consuming older drugs. Our most notable finding, however, is that use of newer drugs tends to lower all types of nondrug medical spending, resulting in a substantial net reduction in the total cost of treating a given condition.

                      What's this?

This article has been cited by other articles:

				D. P. Goldman, G. F. Joyce, and Y. Zheng Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health JAMA, July 4, 2007; 298(1): 61 - 69. [Abstract] [Full Text] [PDF]

				Y. Zhang and S. B. Soumerai Do Newer Prescription Drugs Pay For Themselves? A Reassessment Of The Evidence Health Aff., May 1, 2007; 26(3): 880 - 886. [Abstract] [Full Text] [PDF]

				F. Simon Market Access For Biopharmaceuticals: New Challenges Health Aff., September 1, 2006; 25(5): 1363 - 1370. [Abstract] [Full Text] [PDF]

				V. G. Villagra and T. Ahmed Effectiveness Of A Disease Management Program For Patients With Diabetes Health Aff., July 1, 2004; 23(4): 255 - 266. [Abstract] [Full Text] [PDF]

				M. K. Olson Managing Delegation in the FDA: Reducing Delay in New-Drug Review Journal of Health Politics Policy and Law, June 1, 2004; 29(3): 397 - 430. [Abstract] [PDF]

				C.-W. Tseng, R. H. Brook, E. Keeler, and C. M. Mangione Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients JAMA, July 9, 2003; 290(2): 222 - 227. [Abstract] [Full Text] [PDF]